Objective To investigate the relationship between methylguanine methyltransferase and isocitrate dehydrogenase 1 expression and temozolomide combined with whole brain radiotherapy in the treatment of brain metastases of non-small cell lung cancer. Methods From March 2016 to July 2017,60 non-small cell lung cancer patients with brain metastases were diagnosed based on relevant standards of patients with non-small cell lung cancer brain metastases. The clinical diagnosis and treatment of patients relevant information and data were collected and analyzed. Results In 60 non-small cell lung cancer patients with brain metastases,methylguanine methyltransferase expression and isocitrate dehydrogenase 1 were not expressed in 17 patients,there were 20 patients with isocitrate dehydrogenase 1 expression but methylguanine methyltransferase was not expressed,9 patients with neither methylguanine methyltransferase nor isocitrate dehydrogenase 1,methylguanine methyltransferase and isocitrate dehydrogenase 1 were expressed in 14 patients. There were significant difference in the clinical efficacy and disease control rate of patients because of the different expression of methylguanine methyltransferase and isocitrate dehydrogenase 1(P<0.05).The one-year survival rate of patients that only expressed methylguanine methyltransferase was 65.3%,the two-year survival rate was 43.6%,and the three-year survival rate was 21.1%. The one-year survival rate of patients that only expressed isocitrate dehydrogenase 1 was 93.2%,the two-year survival rate was 74.6%,and the three-year survival rate was 41.6%.The one-year survival rate of patients without methylguanine methyltransferase and isocitrate dehydrogenase 1 was 56.7%,the two-year survival rate was 47.2%,and the three-year survival rate was 19.1%. One-year survival rate of patients with both methylguanine methyltransferase and isocitrate dehydrogenase was 65.3%,the two-year survival rate was 43.6%,and the three-year survival rate was 21.1%. There were significant difference in the one-year survival rate,the two-year survival rate,and the three-year survival rate(P<0.05). Conclusion Temozolomide combined with whole brain radiation therapy in the treatment of non-small cell lung cancer patients with brain metastasis has better clinical efficacy,methyl guanine methyltransferase and isocitrate dehydrogenase 1 expression can effectively reflect clinical treatment results of the combination of temozolomide combined with whole brain radiotherapy.%目的 探究甲基鸟嘌呤甲基转移酶及异柠檬酸脱氢酶1表达与替莫唑胺联合全脑放疗治疗非小细胞肺癌脑转移疗效的关系.方法 选取2016年3月至2017年7月依据相关标准确诊的非小细胞肺癌脑转移60例患者,临床诊治相关资料回顾性整合、分析.结果 甲基鸟嘌呤甲基转移酶表达而异柠檬酸脱氢酶1未表达患者17例,甲基鸟嘌呤甲基转移酶未表达而异柠檬酸脱氢酶1表达患者20例,甲基鸟嘌呤甲基转移酶与异柠檬酸脱氢酶1均未表达患者9例,甲基鸟嘌呤甲基转移酶与异柠檬酸脱氢酶1均表达患者14例.甲基鸟嘌呤甲基转移酶与异柠檬酸脱氢酶1表达情况不同,患者临床治疗有效率及病症控制率均存在一定差异性(P<0.05).甲基鸟嘌呤甲基转移酶表达而异柠檬酸脱氢酶1未表达患者1~3年生存率分别为34.9%、21.3%、0;甲基鸟嘌呤甲基转移酶未表达而异柠檬酸脱氢酶1表达患者一年生存率为93.2%,两年生存率为74.6%,三年生存率为41.6%;甲基鸟嘌呤甲基转移酶与异柠檬酸脱氢酶1均未表达患者1~3年生存率分别为56.7%、47.2%、19.1%;甲基鸟嘌呤甲基转移酶与异柠檬酸脱氢酶1均表达患者一年生存率为65.3%,两年生存率为43.6%,三年生存率为21.1%.甲基鸟嘌呤甲基转移酶与异柠檬酸脱氢酶1表达情况不同,患者1~3年生存率均存在一定差异性(P<0.05).结论 对非小细胞肺癌脑转移患者应用替莫唑胺联合全脑放疗治疗方式实施救治,临床治疗结果显著,甲基鸟嘌呤甲基转移酶及异柠檬酸脱氢酶1的不同表达结合能够有效的反映莫唑胺联合全脑放疗治疗方式的临床治疗结果.
展开▼
